From "primitive spleen epithelioma" to Gaucher's
disease (GD) includes several clinical subtypes with a continuum of clinical findings from a perinatal lethal disorder to an asymptomatic type.
Prior Authorization Criteria For Use of Injectable/Oral Medication in the Treatment of Gaucher's
disease, August 16, 2001, UMC-530-0011.
The NGF also would like to impress on the public that having Gaucher's
disease is no longer a death sentence as there are currently many options, tools, treatments and programs available for those with the disease.
This report provides comprehensive information on the therapeutic development for Gaucher's
Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.
Gynecologic and obstetric aspects of Gaucher's
disease: a survey of 53 patients.
A snapshot of the global therapeutic scenario for Gaucher's
Pulmonary hypertension in type 1 Gaucher's
disease: genetic and epigenetic determinants of phenotype and response to therapy.
Unusual expression of Gaucher's
disease: cardiovascular calcifications in three sibs homozygous for the D409H mutation.
London, May 10 (ANI): Scientists at The Scripps Research Institute have shed light on a mechanism that enables a potential treatment for Gaucher's
disease and other lysosomal storage diseases.
9 December 2009 - Israeli biopharmaceutical company Protalix BioTherapeutics Inc (AMEX: PLX) said today it has completed its New Drug Application (NDA) submission with the US Food and Drug Administration (FDA) for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) for the potential treatment of Gaucher's
The deal also gives Pfizer worldwide rights, except in Israel, to sell a genetically engineered drug called taliglucerase alfa to treat a rare inherited condition known as Gaucher's
has licensed global rights to a treatment for Gaucher's
disease from Protalix.
Protalix expects to complete the company's Phase III trial of prGCD for the treatment of Gaucher's
disease in September, to report top-line results in October and to complete the NDA filing before the end of the year.
Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's